Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STERLING-PMR trial in relapsing polymyalgia rheumatica
ACTRN12623001342606Phase 3Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of methotrexate, leflunomide and prednisolone in polymyalgia rheumatica (PMR) (2 arms), sponsored by University of Adelaide. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
methotrexateleflunomideprednisolone
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on ACTRN12623001342606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001342606.